# A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct05909904/  
OnCo record `nct05909904` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Alcestobart run by BeiGene, completed.

## Summary

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT05909904 by BeiGene, with 160 participants enrolled, started 2023-08-02. Conditions recorded: Head and Neck Squamous Cell Carcinoma and Head and Neck Cancer. Interventions recorded: Tislelizumab, BGB-A425 and LBL-007.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05909904
- Phase: 2
- Setting: A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: BeiGene
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT05909904: https://clinicaltrials.gov/study/NCT05909904

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Alcestobart](https://onco.cc/drugs/alcestobart/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct05909904.json